Liquidia/$LQDA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Liquidia
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
- Ticker
- $LQDA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 216
- Headquarters
- Morrisville, United States
- Website
- www.liquidia.com
Liquidia Metrics
BasicAdvanced
$4B
30.10
$1.48
0.57
-
Price and volume
Market cap
$4B
Beta
0.57
52-week high
$93.61
52-week low
$22.31
Average daily volume
5.8M
Financial strength
Current ratio
2.312
Quick ratio
2.075
Long term debt to equity
0.656
Total debt to equity
0.937
Interest coverage (TTM)
6.33%
Profitability
EBITDA (TTM)
169.768
Gross margin (TTM)
92.54%
Net profit margin (TTM)
30.74%
Operating margin (TTM)
37.39%
Effective tax rate (TTM)
7.29%
Revenue per employee (TTM)
$2,090,000
Management effectiveness
Return on assets (TTM)
27.04%
Return on equity (TTM)
131.82%
Valuation
Price to earnings (TTM)
30.103
Price to revenue (TTM)
8.643
Price to book
20.32
Price to tangible book (TTM)
21.04
Price to free cash flow (TTM)
26.386
Free cash flow yield (TTM)
3.79%
Free cash flow per share (TTM)
1.686
Growth
Revenue change (TTM)
2,233.65%
Earnings per share change (TTM)
-182.32%
3-year revenue growth (CAGR)
193.67%
3-year earnings per share growth (CAGR)
23.37%
What the Analysts think about Liquidia
Analyst ratings (Buy, Hold, Sell) for Liquidia stock.
Analyst projections of the future price of Liquidia stock.
Bulls say / Bears say
YUTREPIA is scaling quickly: second-quarter 2026 sales rose 31% from the prior quarter to $170.4 million, and Liquidia reported a fourth consecutive quarter of increasing profitability. Continued uptake gives the company a growing commercial base. (Liquidia Corporation)
The settlement secures continued YUTREPIA sales for PAH and resolves the pending disputes with United Therapeutics. That removes a major threat to the company’s core commercial business, even though PH-ILD use is being relinquished. (Nasdaq)
L606 offers a potential longer-term growth path beyond YUTREPIA: its global Phase III PH-ILD study has begun enrolling, with results expected in 2029. A successful twice-daily formulation could broaden Liquidia’s product offering, though it remains investigational. (Investing.com)
Liquidia has agreed to remove PH-ILD from YUTREPIA’s label and stop promoting the drug for that use. Losing this indication narrows the product’s commercial opportunity and leaves the company more reliant on PAH sales. (Nasdaq)
The settlement requires substantial payments: $175 million net, followed by another $145.4 million in instalments. These obligations could limit the cash available for commercial investment and clinical development. (StockTitan)
L606 is not a near-term replacement for lost PH-ILD sales: its pivotal study is expected to produce top-line results only in 2029. Meanwhile, management expects research and development spending to rise as trials advance, adding cost before the programme can generate product revenue. (Investing.com, The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.
Liquidia Financial Performance
Revenues and expenses
Liquidia Earnings Performance
Company profitability
Upcoming events
No upcoming events
Liquidia News
AllArticlesVideos
Liquidia Corporation Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money on Your LQDA Investments
Newsfile Corp2 weeks ago
Liquidia shares surge 25% as settlement ends United Therapeutics litigation
Proactive Investors3 weeks ago
This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario.
Barrons3 weeks ago
Funds containing Liquidia
Fund name | Fund size | $LQDA weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.20% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.20% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.11% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.11% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.